Das ACE-Hemmer-induzierte Angioödem

Zusammenfassung

Bei einem ACE-Hemmer-induzierten Angioödem handelt es sich um eine nichtallergische Medikamentennebenwirkung. Hierfür wird der hohe, wahrscheinlich auf einer Abbaustörung beruhende Bradykininspiegel im Plasma verantwortlich gemacht, der die erhöhte vaskuläre Permeabilität auslöst. ACE-Hemmer-induzierte Angioödeme entwickeln sich rasch und kommen in der Kopf-Hals-Region vor allem im Bereich der Lippe, der Zunge und des Kehlkopfes vor. Neue Therapieansätze könnten in naher Zukunft erstmals eine kausale Behandlung des ACE-Hemmer-induzierten Angioödems ermöglichen.

Abstract

ACE-inhibitor induced angioedema is a non-allergic drug-related side effect. Inhibited bradykinin degradation leads to an unphysiological enhanced bradykinin plasma level with vascular leakage and, consequently, to angioedema. ACE-inhibitor induced angioedema develop rapidly in the head and neck region. Typical sites of manifestation are lips, tongue, and larynx. Novel pharmacotherapies may allow a causal treatment of the ACE-inhibitor induced angioedema in the future.

Angioödem - ACE-Hemmer - Bradykinin - Icatibant - Larynxödem

angioedema - ACE-inhibitor - bradykinin - laryngeal edema

Literatur

• 1 Agostoni A, Cicardi M. Drug-induced angioedema without urticaria.  Drug Saf. 2001;  24 599-606
• 2 Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.  N Engl J Med. 2000;  342 145-153
• 3 Brown N J, Vaughan D E. Angiotensin-converting enzyme inhibitors.  Circulation. 1998;  97 1411-1420
• 4 Bas M, Hoffmann T K, Kojda G. Evaluation and management of angioedema of the head and neck.  Curr Opin Otolaryngol Head Neck Surg. 2006;  14 170-175
• 5 Brown N J, Snowden M, Griffin M R. Recurrent angiotensin-converting enzyme inhibitor-associated angioedema.  JAMA. 1997;  278 232-233
• 6 Han E D, MacFarlane R C, Mulligan A N, Scafidi J, Davis III A E. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor.  J Clin Invest. 2002;  109 (8) 1057-1063
• 7 Farmer P J, Bernier S G, Lepage A, Guillemette G, Regoli D, Sirois P. Permeability of endothelial monolayers to albumin is increased by bradykinin and inhibited by prostaglandins.  Am J Physiol Lung Cell Mol Physiol. 2001;  280 (4) L732-L738
• 8 Vleeming W, van Amsterdam J G, Stricker B H, De Wildt D J. ACE inhibitor-induced angioedema. Incidence, prevention and management.  Drug Saf. 1998;  18 171-188
• 9 Messerli F H, Nussberger J. Vasopeptidase inhibition and angio-oedema.  Lancet. 2000;  356 608-609
• 10 Agostoni A, Cicardi M, Cugno M, Zingale L C, Gioffre D, Nussberger J. Angioedema due to angiotensin-converting enzyme inhibitors.  Immunopharmacology. 1999;  44 21-25
• 11 Bork K, Frank J, Grundt B, Schlattmann P, Nussberger J, Kreuz W. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant).  J Allergy Clin Immunol. 2007;  119 (6) 1497-1503
• 12 Nussberger J, Cugno M, Cicardi M, Agostoni A. Local bradykinin generation in hereditary angioedema.  J Allergy Clin Immunol. 1999;  104 (6) 1321-1322
• 13 Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema.  Lancet. 1998;  351 1693-1697
• 14 Adam A, Cugno M, Molinaro G, Perez M, Lepage Y, Agostoni A. Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors.  Lancet. 2002;  359 2088-2089
• 15 Lefebvre J, Murphey L J, Hartert T V, Jiao S R, Simmons W H, Brown N J. Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema.  Hypertension. 2002;  39 460-464
• 16 Bas M, Hoffmann T K, Bier H, Kojda G. Increased C-reactive protein in ACE-inhibitor-induced angioedema.  Br J Clin Pharmacol. 2005;  59 233-238
• 17 O’Ryan F, Poor D B, Hattori M. Intraoperative angioedema induced by angiotensin-converting enzyme inhibitors: overview and case report.  J Oral Maxillofac Surg. 2005;  63 (4) 551-556
• 18 Ajayi A A, Adigun A Q. Angioedema and cough in Nigerian patients receiving ACE inhibitors.  Br J Clin Pharmacol. 2000;  50 81-82
• 19 Bas M, Kojda G, Bier H, Hoffmann T K. Durch ACE-Hemmer induziertes Angioödem des Kopf-Hals-Bereichs. Eine Frage der Zeit?.  HNO. 2004;  52 (10) 886-890
• 20 Morice A H, Brown M J, Higenbottam T. Cough associated with angiotensin converting enzyme inhibition.  J Cardiovasc Pharmacol. 1989;  13 (Suppl 3) S59-S62
• 21 Morice A H, Lowry R, Brown M J, Higenbottam T. Angiotensin-converting enzyme and the cough reflex.  Lancet. 1987;  2 (8568) 1116-1118
• 22 Bas M, Adams V, Suvorava T, Niehues T, Hoffmann T K, Kojda G. Nonallergic angioedema: role of bradykinin.  Allergy. 2007;  62 (8) 842-856
• 23 Bas M, Kojda G. Angioödem nach Einnahme von Irbesartan [Angioedema induced by irbesartan].  Apothekenmagazin. 2005;  23 (10) 254-255
• 24 Hellebrand M C, Kojda G, Hoffmann T K, Bas M. Angioedema due to ACE inhibitors and AT(1) receptor antagonists.  Hautarzt. 2006;  57 808-810
• 25 Chiu A G, Krowiak E J, Deeb Z E. Angioedema associated with angiotensin II receptor antagonists: challenging our knowledge of angioedema and its etiology.  Laryngoscope. 2001;  111 1729-1731
• 26 Davie A P, Dargie H J, McMurray J JV. Role of bradykinin in the vasodilator effects of losartan and enalapril in patients with heart failure.  Circulation. 1999;  100 268-273
• 27 Campbell D J, Krum H, Esler M D. Losartan increases bradykinin levels in hypertensive humans.  Circulation. 2005;  111 315-320
• 28 Pracy J P, McGlashan J A, Walsh R M, Gleeson M J. Angioedema secondary to angiotensin-converting enzyme inhibitors.  J Laryngol Otol. 1994;  108 (8) 696-698
• 29 Bork K, Barnstedt S E, Koch P, Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women.  Lancet. 2000;  356 (9225) 213-217
• 30 Bowen T, Cicardi M, Farkas H. et al . Canadian 2003 International Consensus Algorithm For the Diagnosis, Therapy, and Management of Hereditary Angioedema.  J Allergy Clin Immunol. 2004;  114 629-637
• 31 Bas M, Bier H, Greve J, Kojda G, Hoffmann T K. Novel pharmacotherapy of acute hereditary angioedema with bradykinin B2-receptor antagonist icatibant.  Allergy. 2006;  61 (12) 1490-1492